| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | MK-2206 | GDSC1000 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.3 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.033 | 0.3 |
| mRNA | EX-527 | GDSC1000 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | CGP-60474 | GDSC1000 | pan-cancer | AAC | -0.052 | 0.3 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.05 | 0.3 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |